We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Tissue Spacers Reduce Risk of Rectal Injury

By HospiMedica International staff writers
Posted on 19 May 2011
Injecting a tissue spacer in the prostate-rectal inter-space is an effective way to reduce the rectal radiation dose for prostate cancer patients receiving radiation therapy, according to a new study.

Researchers at the Cancer Center of Irvine (CA, USA) conducted a study involving 34 prostate carcinoma patients that were injected with a tissue spacer compound to increase the separation between the prostate and the rectum during the radiation therapy they were receiving. More...
The patients were imaged via magnetic resonance imaging (MRI) preinjection, postinjection, and every two weeks until the end of treatment to monitor any changes.

The researchers found that the spacer generated an additional one centimeter (on average) separation between the prostate and rectum, resulting in a significant reduction in the rectal dose administered and causing very little damage to the rectum. The reductions in severe rectal radiation burns--the most serious risk of injury from the radiation--were essentially eliminated. This enabled the radiation oncologists to increase the dose to the posterior prostate without concern of damaging the rectum. The study was presented at the Cancer Imaging and Radiation Therapy Symposium, held during April 2011 in Atlanta (GA, USA).

"Removing rectal injury from the treatment essentially makes radiation therapy the treatment of choice for prostate cancer," said senior author and study presenter Kenneth Tokita, MD. "The ability to reach almost perfect cure rates and minimal injury is the dream of all cancer specialists. We are now wondering where else this may benefit cancer patients in radiation therapy treatments."

Treatment for prostate cancer may involve active surveillance (monitoring for tumor progress or symptoms), surgery (radical prostatectomy), radiation therapy including brachytherapy and external beam radiation therapy, high-intensity focused ultrasound (HIFU), chemotherapy, cryosurgery, hormonal therapy, or some combination. Which option is best depends on the stage of the disease, the Gleason score, and the prostate-specific antigen (PSA) level. Other important factors are age, general health, and patient views about potential treatments and their possible side effects.

Related Links:
Cancer Center of Irvine



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Syringe Pump
SP50 Series
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.